How Meningitis Vaccines Work: MenACWY, MenB, Hib & PCV
A scientific guide explaining how the principal bacterial meningitis vaccines work, their antigen technologies, immune mechanisms, and limitations.
MENINGVAX / SCIENTIFIC INSIGHTS / BLOG 001
How Do Meningitis Vaccines Work?
The science behind MenACWY, MenB, Hib, and pneumococcal vaccines
A molecular explanation of protective antibodies, bacterial antigens, conjugate vaccine technology, and the limits of vaccine-induced protection.
01 / THE ESSENTIAL ANSWER
How does a meningitis vaccine protect the body?
Meningitis vaccines expose the immune system to selected microbial antigens without causing the targeted invasive disease. This stimulates antigen-specific immune responses, including antibodies capable of recognizing important components of the pathogen.
When subsequent exposure occurs, circulating antibodies and other immune mechanisms can help prevent invasive infection. The precise protection mechanism depends on the organism and vaccine technology.
No single vaccine protects against all causes of meningitis. MenACWY and MenB vaccines target different meningococcal serogroups, while Hib and pneumococcal vaccines target different bacterial species.
02 / MECHANISM OF IMMUNITY
Antigens, antibodies, and complement
Meningococcal vaccines induce antibodies against specific capsular or protein antigens. Certain antibodies can initiate the classical complement pathway, resulting in formation of the membrane attack complex and bacterial killing.
Functional antibody activity can be assessed through serum bactericidal antibody assays (SBA), an established immunological endpoint in meningococcal vaccine evaluation.
03 / MENINGOCOCCAL CONJUGATE VACCINES
How MenACWY vaccines work
MenACWY vaccines target Neisseria meningitidis serogroups A, C, W, and Y. Their capsular polysaccharides are chemically linked to carrier proteins, improving the immune response compared with unconjugated polysaccharide antigens.
Protein conjugation supports T-cell-dependent responses and immunological memory, which are particularly important in pediatric vaccination.
04 / PROTEIN-BASED MENINGOCOCCAL VACCINES
Why MenB vaccines use a different strategy
Serogroup B meningococcal capsular polysaccharide resembles human polysialic acid, making it unsuitable as the conventional antigen for broad MenB vaccination.
Licensed MenB vaccines therefore use selected protein antigens, including factor H-binding protein (fHbp), and, in some formulations, additional proteins and outer membrane vesicle components.
Genome-based antigen discovery helped identify candidate meningococcal proteins and contributed to the development of multicomponent MenB vaccine approaches.
05 / HAEMOPHILUS INFLUENZAE TYPE B
How Hib conjugate vaccines prevent meningitis
Hib vaccines target the polyribosylribitol phosphate (PRP) capsule of Haemophilus influenzae type b. Linking PRP to a carrier protein enhances immune responses in young children.
The introduction of Hib conjugate vaccines substantially reduced invasive Hib disease and Hib meningitis in populations achieving high vaccine coverage.
Long-term observational studies document major changes in childhood Hib meningitis epidemiology after conjugate vaccine introduction.
READ THE STUDY ↗06 / STREPTOCOCCUS PNEUMONIAE
How pneumococcal vaccines reduce meningitis risk
Pneumococcal conjugate vaccines stimulate immune responses against selected capsular serotypes of Streptococcus pneumoniae, a major cause of bacterial meningitis.
Vaccination helps prevent invasive disease caused by covered serotypes. Some conjugate vaccine programs also reduce nasopharyngeal carriage of covered types, providing indirect protection within communities.
Surveillance remains important because pneumococcal serotypes not included in a particular vaccine may continue to cause disease.
EXPLORE PNEUMOCOCCAL VACCINES ↗07 / VACCINE COMPARISON
MenACWY vs MenB vs Hib vs pneumococcal vaccines
| Vaccine | Bacterial target | Antigen technology |
|---|---|---|
| MenACWY | Meningococcal A, C, W, Y | Capsular polysaccharide conjugates |
| MenB | Meningococcal B | Recombinant proteins; some formulations include OMVs |
| Hib | H. influenzae type b | PRP polysaccharide conjugate |
| Pneumococcal conjugate | Selected S. pneumoniae serotypes | Capsular polysaccharide conjugates |
OMV = outer membrane vesicle; PRP = polyribosylribitol phosphate. Vaccine formulation and availability vary by product and country.
08 / PROTECTION AND LIMITATIONS
Why vaccination cannot eliminate every meningitis risk
Vaccine protection depends on factors including targeted organisms, antigenic variation, individual immune responses, time since vaccination, and coverage within the population.
Viral meningitis, fungal meningitis, and meningitis caused by bacterial types not included in a particular vaccine remain possible.
Vaccination is a cornerstone of prevention, but suspected bacterial meningitis still requires immediate medical assessment, regardless of vaccination history.
09 / RESEARCH ANSWERS AND REFERENCES
Questions and scientific evidence
Does MenACWY protect against meningococcal B?
No. MenACWY targets serogroups A, C, W, and Y. MenB vaccines use separate antigens to target serogroup B strains.
Can one person need different meningitis vaccines?
Yes. Different vaccines prevent disease caused by different bacteria or serogroups. Recommendations depend on age, medical risk, and local immunization guidance.
Do meningitis vaccines prevent viral meningitis?
The bacterial vaccines discussed here do not prevent viral meningitis. Some other vaccines can reduce meningitis associated with particular viral infections.
Peer-reviewed references
- Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine. 2009. PubMed ↗
- Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development. Full text ↗
- Impact of routine vaccination with a conjugate Haemophilus influenzae type b vaccine. PubMed ↗
- Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis. PubMed ↗
- Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000. PubMed ↗
Explore the science in greater depth
Educational scientific content. Individual vaccine eligibility and schedules should follow applicable clinical and public-health recommendations.